Michelle A Gaylord, Melissa Larrier, Donna Giordano-Schmidt, Christopher D Grube, Suddham Singh, Ha H Nguyen, Andrew McKeen, Charles Y Tan, Annaliesa S Anderson, Warren V Kalina, Danka Pavliakova, Peter C Giardina
Six serotypes (Ia, Ib, II, III, IV, and V) cause nearly all group B streptococcal (GBS) disease globally. Capsular polysaccharide (CPS) conjugate vaccines aim to prevent GBS disease, however, licensure of a vaccine would depend on a standardized serological assay for measuring anti-CPS IgG responses. A multiplex direct Luminex-based immunoassay (dLIA) has been developed to simultaneously measure the concentration of serum IgG specific for the six prevalent GBS CPS serotypes. Assay validation was performed using serum samples obtained from human subjects vaccinated with an investigational 6-valent GBS CPS conjugate vaccine...
December 31, 2024: Human Vaccines & Immunotherapeutics